IFNα Kinoid® (IFNa-K)
Systemic Lupus Erythematosus (SLE)
Phase 2Inactive/On Hold
Key Facts
About Neovacs
Neovacs is a publicly traded French biotech with a bifurcated strategy combining internal R&D and external investment. Its primary internal focus is the Kinoid® technology platform, which develops therapeutic vaccines targeting specific cytokines in diseases like lupus and allergies. The company has faced significant financial and restructuring challenges, leading to a halted pipeline and a shift towards an investment-focused model to generate value and potentially restart its own development programs.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| Cenerimod | Idorsia | Phase 3 |
| CLN-978 | Cullinan Therapeutics | Phase 1 |
| Telitacicept | Vor Biopharma | Marketed |
| Dapirolizumab Pegol | Silence Therapeutics | Phase 3 |
| rese-cel (resecabtagene autoleucel) | Cabaletta Bio | Phase 1/2 |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| nipocalimab | Johnson and Johnson Innovative Medicine | Phase 3 |
| Brepocitinib (PF-06700841) | Priovant Therapeutics | Phase 3 |
| aiSLE® DX Flare Risk Index | Progentec Diagnostics | Commercial |
| aiSLE® DX Disease Activity Index | Progentec Diagnostics | Commercial |
| OASIS Study (Digital Biomarkers) | Progentec Diagnostics | Clinical Study |